Pérez-Manauta J

Idioma: Español
Referencias bibliográficas: 16
Paginas: 305-308
Archivo PDF: 33.38 Kb.

FRAGMENTO

PROCTITIS Y PROCTOSIGMOIDITIS

Inducción de la remisión

El objetivo del tratamiento está dirigido a alivar la inflamación mucosa, la remisión de los síntomas y por lo tanto la mejoría en la calidad de vida. El plan terapéutico será determinado en parte por la preferencia del paciente ya que tanto la terapia oral como la tópica son efectivas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hanauer S. New lessons: classic treatment, expanding options in ulcerative colitis. Colorectal Dis 2006; 8 (Suppl): 20-4.

2. Travis S. Review articles: induction therapy for patients with active ulcerative colitis. Aliment Pharmacol Ther 2006; 24: 10-6.

3. Haghighi DB, Lashner BA. Left-sided ulcerative colitis. Gastroenterol Clin N Am 2004; 33: 271-84.

4. Feagan B. Medical Management of Ulcerative Colitis in 2006: What’s on the Horizon? Am J Gastroenterol 2007; 102: S7-S13.

5. Hanauer S. Medical Therapy for Ulcerative Colitis 2004. Gastroenterol 2004; 126: 1582-92.

6. Kornbluth A, Sachar D. Practice Guidelines. Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004.

7. Qureshi A, Cohen R. Mesalamine delivery system: do they really make much difference? Advanced Drug Delivery Reviews 2005; 57: 281-302.

8. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adult. Gut 2006; 53: 1-16.

9. Hanauer S, Sandborn W, Kornbluth A, Katz S, Safdi M, Woogen S, et al. Delayed- Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial. Am J Gastroenterol 2005; 100: 2478-85.

10. Danese S, Semerro S, Papa A, Roberto I, Scaldeferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227-36.

11. Meuwissen S, Crusius B, Peña AS, Dekker-Saeys AJ, Dijkmans C. Spondyloarthropathy and Idiopathic Inflammatory Bowel Diseases. Inflamm Bowel Dis 1997; 3: 25-37.

12. Holden W, Orchard T, Wordsworth P. Artritis enteropática. Rheumatic Dis Clin N Am 2003; 5: 443-57.

13. Storch I, Sachar D, Katz S. Pulmonary Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2003; 9: 104-15.

14. Lebwohl M, Lebwohl O. Cutaneous Manifestations of Inflammatory Bowel Disease. Infl Bowel Dis 1998; 4: 142-8.

15. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2004; 10: 135-9.

16. Barrie A, Plevy S. Treatment of Inmmune-Mediated Extraintestinal Manifestations of Inflammatory Bowel Disease with Infliximab. Gastroenterol Clin N Am 2006; 35: 883-93.